⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 9, 2024Neurology

Living with Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa for Symptom Management in Advanced Parkinson’s Disease: A Patient Experience Study (P9-3.006)

Michael J. Soileau Jason Aldred Zach Baldwin Connie Yan Triza Brion Alex Bellenger JeeHee Suh Megha Shah Pavnit Kukreja Maurizio Facheris Anand R. Shewale Rajeev Kumar

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

To understand people with advanced Parkinson's Disease (aPD) experience, satisfaction, ease of use, and convenience with the foslevodopa/foscarbidopa (LDp/CDp) delivery system.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Soileau et al. (2024) studied this question.

synapsesocial.com/papers/68e6fcc5b6db64358767746c https://doi.org/10.1212/wnl.0000000000205745

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Continuous subcutaneous foslevodopa/foscarbidopa infusion for advanced parkinson’s diseaseLate-Phase Clinical Trial · 2026
2Real-world Tolerability of Foslevodopa/Foscarbidopa Subcutaneous Infusion in Parkinson’s Disease: Discontinuation Beyond Titration (S26.006)Early-Phase Clinical Trial · 2026
3Continuous Subcutaneous Foslevodopa/Foscarbidopa in Advanced Parkinson's DiseaseObservational Study · 2026 · 1 citations
4Observational Retrospective Cohort of Patient Support Program Data on Practical Experiences of Treatment with Foslevodopa/Foscarbidopa in Advanced Parkinson’s Disease: The ORCHESTRA StudyCohort Study · 2026 · 2 citations
5Continuous subcutaneous levodopa and foslevodopa infusion therapy for motor symptoms of Parkinson disease: A systematic review of observational studiesSystematic Review · 2026 · 1 citations